Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 212

1.

Serum uric acid as a marker of disease risk, severity, and survival in systemic sclerosis-related pulmonary arterial hypertension.

Simpson CE, Damico RL, Hummers L, Khair RM, Kolb TM, Hassoun PM, Mathai SC.

Pulm Circ. 2019 Jul 29;9(3):2045894019859477. doi: 10.1177/2045894019859477. eCollection 2019 Jul-Sep.

2.

Myocardial Fibrosis as a Potential Maladaptive Feature of Right Ventricle Remodeling in Pulmonary Hypertension.

Simpson CE, Hassoun PM.

Am J Respir Crit Care Med. 2019 Sep 15;200(6):662-663. doi: 10.1164/rccm.201906-1154ED. No abstract available.

3.

SU5416 does not attenuate early RV angiogenesis in the murine chronic hypoxia PH model.

Peloquin GL, Johnston L, Damarla M, Damico RL, Hassoun PM, Kolb TM.

Respir Res. 2019 Jun 17;20(1):123. doi: 10.1186/s12931-019-1079-x.

4.

Validation of the REVEAL Prognostic Equation and Risk Score Calculator in Incident Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.

Mullin CJ, Khair RM, Damico RL, Kolb TM, Hummers LK, Hassoun PM, Steen VD, Mathai SC; PHAROS Investigators.

Arthritis Rheumatol. 2019 Oct;71(10):1691-1700. doi: 10.1002/art.40918. Epub 2019 Aug 26.

PMID:
31066998
5.

Ventricular mass as a prognostic imaging biomarker in incident pulmonary arterial hypertension.

Simpson CE, Damico RL, Kolb TM, Mathai SC, Khair RM, Sato T, Bourji K, Tedford RJ, Zimmerman SL, Hassoun PM.

Eur Respir J. 2019 Apr 4;53(4). pii: 1802067. doi: 10.1183/13993003.02067-2018. Print 2019 Apr. No abstract available.

PMID:
30705128
6.

Disconnect between Fibrotic Response and Right Ventricular Dysfunction.

Crnkovic S, Egemnazarov B, Damico R, Marsh LM, Nagy BM, Douschan P, Atsina K, Kolb TM, Mathai SC, Hooper JE, Ghanim B, Klepetko W, Fruhwald F, Lassner D, Olschewski A, Olschewski H, Hassoun PM, Kwapiszewska G.

Am J Respir Crit Care Med. 2019 Jun 15;199(12):1550-1560. doi: 10.1164/rccm.201809-1737OC.

PMID:
30557518
7.

Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update.

Vonk Noordegraaf A, Chin KM, Haddad F, Hassoun PM, Hemnes AR, Hopkins SR, Kawut SM, Langleben D, Lumens J, Naeije R.

Eur Respir J. 2019 Jan 24;53(1). pii: 1801900. doi: 10.1183/13993003.01900-2018. Print 2019 Jan.

8.

Discordance between Imaging Modalities in the Evaluation of Chronic Thromboembolic Pulmonary Hypertension: A Combined Experience from Two Academic Medical Centers.

Furfaro D, Azadi J, Housten T, Kolb TM, Damico RL, Hassoun PM, Chin K, Mathai SC.

Ann Am Thorac Soc. 2019 Feb;16(2):277-280. doi: 10.1513/AnnalsATS.201809-588RL. No abstract available.

PMID:
30359536
9.

Risk assessment in scleroderma patients with newly diagnosed pulmonary arterial hypertension: application of the ESC/ERS risk prediction model.

Mercurio V, Diab N, Peloquin G, Housten-Harris T, Damico R, Kolb TM, Mathai SC, Hassoun PM.

Eur Respir J. 2018 Oct 18;52(4). pii: 1800497. doi: 10.1183/13993003.00497-2018. Print 2018 Oct. No abstract available.

PMID:
30262575
10.

Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research Statement.

Lahm T, Douglas IS, Archer SL, Bogaard HJ, Chesler NC, Haddad F, Hemnes AR, Kawut SM, Kline JA, Kolb TM, Mathai SC, Mercier O, Michelakis ED, Naeije R, Tuder RM, Ventetuolo CE, Vieillard-Baron A, Voelkel NF, Vonk-Noordegraaf A, Hassoun PM; American Thoracic Society Assembly on Pulmonary Circulation.

Am J Respir Crit Care Med. 2018 Aug 15;198(4):e15-e43. doi: 10.1164/rccm.201806-1160ST.

PMID:
30109950
11.

Pulmonary hypertension: the unaddressed global health burden.

Rich S, Haworth SG, Hassoun PM, Yacoub MH.

Lancet Respir Med. 2018 Aug;6(8):577-579. doi: 10.1016/S2213-2600(18)30268-6. Epub 2018 Jun 29. No abstract available.

PMID:
30072105
12.

Supply and Demand: Micro(vascular) Economics of the Right Ventricle in Pulmonary Hypertension.

Kolb TM, Hassoun PM.

Am J Respir Cell Mol Biol. 2018 Oct;59(4):410-411. doi: 10.1165/rcmb.2018-0203ED. No abstract available.

PMID:
29995431
13.

Biomarkers for Pulmonary Vascular Remodeling in Systemic Sclerosis: A Pathophysiological Approach.

Odler B, Foris V, Gungl A, Müller V, Hassoun PM, Kwapiszewska G, Olschewski H, Kovacs G.

Front Physiol. 2018 Jun 19;9:587. doi: 10.3389/fphys.2018.00587. eCollection 2018. Review.

14.

Phenotyping pulmonary hypertension in systemic sclerosis: a moving target.

Mercurio V, Hassoun PM.

Pulm Circ. 2018 Apr-Jun;8(2):2045894018785247. doi: 10.1177/2045894018785247. No abstract available.

15.

Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis.

Launay D, Montani D, Hassoun PM, Cottin V, Le Pavec J, Clerson P, Sitbon O, Jaïs X, Savale L, Weatherald J, Sobanski V, Mathai SC, Shafiq M, Cordier JF, Hachulla E, Simonneau G, Humbert M.

PLoS One. 2018 May 15;13(5):e0197112. doi: 10.1371/journal.pone.0197112. eCollection 2018.

16.

Pulmonary Effective Arterial Elastance as a Measure of Right Ventricular Afterload and Its Prognostic Value in Pulmonary Hypertension Due to Left Heart Disease.

Tampakakis E, Shah SJ, Borlaug BA, Leary PJ, Patel HH, Miller WL, Kelemen BW, Houston BA, Kolb TM, Damico R, Mathai SC, Kasper EK, Hassoun PM, Kass DA, Tedford RJ.

Circ Heart Fail. 2018 Apr;11(4):e004436. doi: 10.1161/CIRCHEARTFAILURE.117.004436.

17.

Pulmonary arterial hypertension and atrial arrhythmias: incidence, risk factors, and clinical impact.

Mercurio V, Peloquin G, Bourji KI, Diab N, Sato T, Enobun B, Housten-Harris T, Damico R, Kolb TM, Mathai SC, Tedford RJ, Tocchetti CG, Hassoun PM.

Pulm Circ. 2018 Apr-Jun;8(2):2045894018769874. doi: 10.1177/2045894018769874. Epub 2018 Mar 26.

18.

Focused Review of Perioperative Care of Patients with Pulmonary Hypertension and Proposal of a Perioperative Pathway.

Steppan J, Diaz-Rodriguez N, Barodka VM, Nyhan D, Pullins E, Housten T, Damico RL, Mathai SC, Hassoun PM, Berkowitz DE, Maxwell BG, Kolb TM.

Cureus. 2018 Jan 15;10(1):e2072. doi: 10.7759/cureus.2072. Review.

19.

Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report.

Elinoff JM, Agarwal R, Barnett CF, Benza RL, Cuttica MJ, Gharib AM, Gray MP, Hassoun PM, Hemnes AR, Humbert M, Kolb TM, Lahm T, Leopold JA, Mathai SC, McLaughlin VV, Preston IR, Rosenzweig EB, Shlobin OA, Steen VD, Zamanian RT, Solomon MA.

Am J Respir Crit Care Med. 2018 Jul 15;198(2):166-174. doi: 10.1164/rccm.201710-2093PP. No abstract available.

20.

New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension.

Mercurio V, Bianco A, Campi G, Cuomo A, Diab N, Mancini A, Parrella P, Petretta M, Hassoun PM, Bonaduce D.

Curr Med Chem. 2019;26(16):2844-2864. doi: 10.2174/0929867325666180201095743.

PMID:
29421995
21.

Right Ventricular Myofilament Functional Differences in Humans With Systemic Sclerosis-Associated Versus Idiopathic Pulmonary Arterial Hypertension.

Hsu S, Kokkonen-Simon KM, Kirk JA, Kolb TM, Damico RL, Mathai SC, Mukherjee M, Shah AA, Wigley FM, Margulies KB, Hassoun PM, Halushka MK, Tedford RJ, Kass DA.

Circulation. 2018 May 29;137(22):2360-2370. doi: 10.1161/CIRCULATIONAHA.117.033147. Epub 2018 Jan 19.

22.

Imatinib Is Protective Against Ischemia-Reperfusion Injury in an Ex Vivo Rabbit Model of Lung Injury.

Magruder JT, Grimm JC, Crawford TC, Johnston L, Santhanam L, Stephens RS, Berkowitz DE, Shah AS, Bush EL, Damarla M, Damico RL, Hassoun PM, Kim BS.

Ann Thorac Surg. 2018 Mar;105(3):950-956. doi: 10.1016/j.athoracsur.2017.10.002. Epub 2017 Dec 28.

PMID:
29289364
23.

The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study.

Sato T, Ambale-Venkatesh B, Lima JAC, Zimmerman SL, Tedford RJ, Fujii T, Hulme OL, Pullins EH, Corona-Villalobos CP, Zamanian RT, Minai OA, Girgis RE, Chin K, Khair R, Damico RL, Kolb TM, Mathai SC, Hassoun PM.

Pulm Circ. 2018 Jan-Mar;8(1):2045893217748307. doi: 10.1177/2045893217748307. Epub 2017 Dec 18.

24.

Right ventricular longitudinal strain is diminished in systemic sclerosis compared with idiopathic pulmonary arterial hypertension.

Mukherjee M, Mercurio V, Tedford RJ, Shah AA, Hsu S, Mullin CJ, Sato T, Damico R, Kolb TM, Mathai SC, Hassoun PM.

Eur Respir J. 2017 Nov 22;50(5). pii: 1701436. doi: 10.1183/13993003.01436-2017. Print 2017 Nov. No abstract available.

25.

PVDOMICS: A Multi-Center Study to Improve Understanding of Pulmonary Vascular Disease Through Phenomics.

Hemnes AR, Beck GJ, Newman JH, Abidov A, Aldred MA, Barnard J, Berman Rosenzweig E, Borlaug BA, Chung WK, Comhair SAA, Erzurum SC, Frantz RP, Gray MP, Grunig G, Hassoun PM, Hill NS, Horn EM, Hu B, Lempel JK, Maron BA, Mathai SC, Olman MA, Rischard FP, Systrom DM, Tang WHW, Waxman AB, Xiao L, Yuan JX, Leopold JA; PVDOMICS Study Group.

Circ Res. 2017 Oct 27;121(10):1136-1139. doi: 10.1161/CIRCRESAHA.117.311737. No abstract available.

26.

Evaluation of criteria for exercise-induced pulmonary hypertension in patients with resting pulmonary hypertension.

Mullin CJ, Hsu S, Amancherla K, Wand A, Rhodes P, Leary PJ, Mukherjee M, Damico RL, Kolb TM, Mathai SC, Hassoun PM, Tedford RJ.

Eur Respir J. 2017 Sep 20;50(3). pii: 1700784. doi: 10.1183/13993003.00784-2017. Print 2017 Sep. No abstract available.

27.

XOR inhibition with febuxostat accelerates pulmonary endothelial barrier recovery and improves survival in lipopolysaccharide-induced murine sepsis.

Damarla M, Johnston LF, Liu G, Gao L, Wang L, Varela L, Kolb TM, Kim BS, Damico RL, Hassoun PM.

Physiol Rep. 2017 Aug;5(15). pii: e13377. doi: 10.14814/phy2.13377.

28.

Improvement in Right Ventricular Strain with Ambrisentan and Tadalafil Upfront Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.

Mercurio V, Mukherjee M, Tedford RJ, Zamanian RT, Khair RM, Sato T, Minai OA, Torres F, Girgis RE, Chin K, Damico R, Kolb TM, Mathai SC, Hassoun PM.

Am J Respir Crit Care Med. 2018 Feb 1;197(3):388-391. doi: 10.1164/rccm.201704-0789LE. No abstract available.

29.

Poor survival in patients with scleroderma and pulmonary hypertension due to heart failure with preserved ejection fraction.

Bourji KI, Kelemen BW, Mathai SC, Damico RL, Kolb TM, Mercurio V, Cozzi F, Tedford RJ, Hassoun PM.

Pulm Circ. 2017 Apr-Jun;7(2):409-420. doi: 10.1177/2045893217700438. Epub 2017 Mar 27.

30.

Pulmonary arterial hypertension: screening challenges in systemic sclerosis and future directions.

Diab N, Hassoun PM.

Eur Respir J. 2017 May 11;49(5). pii: 1700522. doi: 10.1183/13993003.00522-2017. Print 2017 May. No abstract available.

31.

Correction: Disruption of Nrf2 Impairs the Resolution of Hyperoxia-Induced Acute Lung Injury and Inflammation in Mice.

Reddy NM, Kleeberger SR, Kensler TW, Yamamoto M, Hassoun PM, Reddy SP.

J Immunol. 2017 May 1;198(9):3755. doi: 10.4049/jimmunol.1700291. No abstract available.

32.

Differences in Right Ventricular Functional Changes during Treatment between Systemic Sclerosis-associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension.

Argula RG, Karwa A, Lauer A, Gregg D, Silver RM, Feghali-Bostwick C, Schanpp LM, Egbert K, Usher BW, Ramakrishnan V, Hassoun PM, Strange C.

Ann Am Thorac Soc. 2017 May;14(5):682-689. doi: 10.1513/AnnalsATS.201608-655OC.

33.

Exhaled nitric oxide in pulmonary arterial hypertension associated with systemic sclerosis.

Cao Z, Mathai SC, Hummers LK, Shah AA, Wigley FM, Lechtzin N, Hassoun PM, Girgis RE.

Pulm Circ. 2016 Dec;6(4):545-550. doi: 10.1086/688768.

34.

Pulmonary Arterial Compliance in Acute Respiratory Distress Syndrome: Clinical Determinants and Association With Outcome From the Fluid and Catheter Treatment Trial Cohort.

Metkus TS, Tampakakis E, Mullin CJ, Houston BA, Kolb TM, Mathai SC, Damico R, Maron BA, Hassoun PM, Brower RG, Tedford RJ.

Crit Care Med. 2017 Mar;45(3):422-429. doi: 10.1097/CCM.0000000000002186.

35.

Heart Rate Dependence of the Pulmonary Resistance x Compliance (RC) Time and Impact on Right Ventricular Load.

Metkus TS, Mullin CJ, Grandin EW, Rame JE, Tampakakis E, Hsu S, Kolb TM, Damico R, Hassoun PM, Kass DA, Mathai SC, Tedford RJ.

PLoS One. 2016 Nov 18;11(11):e0166463. doi: 10.1371/journal.pone.0166463. eCollection 2016.

36.

Time to consider death in clinical trials for PAH.

Hassoun PM.

Lancet Respir Med. 2016 Nov;4(11):849-850. doi: 10.1016/S2213-2600(16)30308-3. Epub 2016 Oct 11. No abstract available.

PMID:
27745819
37.

Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension.

Bonnet S, Provencher S, Guignabert C, Perros F, Boucherat O, Schermuly RT, Hassoun PM, Rabinovitch M, Nicolls MR, Humbert M.

Am J Respir Crit Care Med. 2017 Mar 1;195(5):583-595. doi: 10.1164/rccm.201607-1515PP. Review. No abstract available.

38.

Hepatoma-derived Growth Factor Predicts Disease Severity and Survival in Pulmonary Arterial Hypertension.

Yang J, Nies MK, Fu Z, Damico R, Korley FK, Hassoun PM, Ivy DD, Austin ED, Everett AD.

Am J Respir Crit Care Med. 2016 Nov 15;194(10):1264-1272.

39.

Sildenafil for pulmonary hypertension complicating idiopathic pulmonary fibrosis: a rationale grounded in basic science.

Hassoun PM, Nathan SD.

Eur Respir J. 2016 Jun;47(6):1615-7. doi: 10.1183/13993003.00395-2016. No abstract available.

40.

Identifying microRNAs targeting Wnt/β-catenin pathway in end-stage idiopathic pulmonary arterial hypertension.

Wu D, Talbot CC Jr, Liu Q, Jing ZC, Damico RL, Tuder R, Barnes KC, Hassoun PM, Gao L.

J Mol Med (Berl). 2016 Aug;94(8):875-85. doi: 10.1007/s00109-016-1426-z. Epub 2016 May 18.

41.

Trials and Tribulations of Therapies for the Acute Respiratory Distress Syndrome.

Damarla M, Hassoun PM.

Crit Care Med. 2016 Jun;44(6):e453-4. doi: 10.1097/CCM.0000000000001573. No abstract available.

42.

Right Ventricular Functional Reserve in Pulmonary Arterial Hypertension.

Hsu S, Houston BA, Tampakakis E, Bacher AC, Rhodes PS, Mathai SC, Damico RL, Kolb TM, Hummers LK, Shah AA, McMahan Z, Corona-Villalobos CP, Zimmerman SL, Wigley FM, Hassoun PM, Kass DA, Tedford RJ.

Circulation. 2016 Jun 14;133(24):2413-22. doi: 10.1161/CIRCULATIONAHA.116.022082. Epub 2016 May 11.

43.

The Minimal Important Difference in Borg Dyspnea Score in Pulmonary Arterial Hypertension.

Khair RM, Nwaneri C, Damico RL, Kolb T, Hassoun PM, Mathai SC.

Ann Am Thorac Soc. 2016 Jun;13(6):842-9. doi: 10.1513/AnnalsATS.201512-824OC.

44.

Right atrial pressure/pulmonary artery wedge pressure ratio: A more specific predictor of survival in pulmonary arterial hypertension.

Fares WH, Bellumkonda L, Tonelli AR, Carson SS, Hassoun PM, Trow TK, Herzog EL, Kaminski N, Kholdani CA, Zhang L, Zhou Y, Hammel JP, Dweik RA.

J Heart Lung Transplant. 2016 Jun;35(6):760-7. doi: 10.1016/j.healun.2015.12.028. Epub 2016 Jan 8.

PMID:
26856665
45.

Prognostic Significance of Biomarkers in Pulmonary Arterial Hypertension.

Al-Naamani N, Palevsky HI, Lederer DJ, Horn EM, Mathai SC, Roberts KE, Tracy RP, Hassoun PM, Girgis RE, Shimbo D, Post WS, Kawut SM; ASA-STAT Study Group.

Ann Am Thorac Soc. 2016 Jan;13(1):25-30. doi: 10.1513/AnnalsATS.201508-543OC.

46.

Health-related Quality of Life and Survival in Pulmonary Arterial Hypertension.

Mathai SC, Suber T, Khair RM, Kolb TM, Damico RL, Hassoun PM.

Ann Am Thorac Soc. 2016 Jan;13(1):31-9. doi: 10.1513/AnnalsATS.201412-572OC.

47.

Identification of Rare Variants in ATP8B4 as a Risk Factor for Systemic Sclerosis by Whole-Exome Sequencing.

Gao L, Emond MJ, Louie T, Cheadle C, Berger AE, Rafaels N, Vergara C, Kim Y, Taub MA, Ruczinski I, Mathai SC, Rich SS, Nickerson DA, Hummers LK, Bamshad MJ, Hassoun PM, Mathias RA; National Heart, Lung, and Blood Institute GO Exome Sequencing Project, Barnes KC.

Arthritis Rheumatol. 2016 Jan;68(1):191-200. doi: 10.1002/art.39449.

48.

Bidimensional measurements of right ventricular function for prediction of survival in patients with pulmonary hypertension: comparison of reproducibility and time of analysis with volumetric cardiac magnetic resonance imaging analysis.

Corona-Villalobos CP, Kamel IR, Rastegar N, Damico R, Kolb TM, Boyce DM, Sager AE, Skrok J, Shehata ML, Vogel-Claussen J, Bluemke DA, Girgis RE, Mathai SC, Hassoun PM, Zimmerman SL.

Pulm Circ. 2015 Sep;5(3):527-37. doi: 10.1086/682229.

49.

Macrophage Migration Inhibitory Factor: A Novel Inhibitor of Apoptosis Signal-Regulating Kinase 1-p38-Xanthine Oxidoreductase-Dependent Cigarette Smoke-Induced Apoptosis.

Fallica J, Varela L, Johnston L, Kim B, Serebreni L, Wang L, Damarla M, Kolb TM, Hassoun PM, Damico R.

Am J Respir Cell Mol Biol. 2016 Apr;54(4):504-14. doi: 10.1165/rcmb.2014-0403OC.

50.

Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.

Hassoun PM, Zamanian RT, Damico R, Lechtzin N, Khair R, Kolb TM, Tedford RJ, Hulme OL, Housten T, Pisanello C, Sato T, Pullins EH, Corona-Villalobos CP, Zimmerman SL, Gashouta MA, Minai OA, Torres F, Girgis RE, Chin K, Mathai SC.

Am J Respir Crit Care Med. 2015 Nov 1;192(9):1102-10. doi: 10.1164/rccm.201507-1398OC.

Supplemental Content

Loading ...
Support Center